CHRS
HealthcareCoherus Oncology, Inc.
$1.44
+$0.07 (+5.11%)
Jan 5, 2026
Price History (1Y)
Analysis
Coherus Oncology, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $174.05 million and 158 employees. The company's revenue has grown significantly year-over-year at a rate of 91.2%, reaching $277.73 million in the trailing twelve months. The company's financial health is characterized by high profitability, with gross margins of 56.3% and profit margins of 55.8%. However, its operating margin stands at -365.0%, indicating significant losses. The company's return on assets (ROA) is -10.3%, while the debt-to-equity ratio is 61.89. The current ratio is 1.24, suggesting that the company has sufficient liquidity to meet its short-term obligations. Coherus Oncology's valuation metrics include a price-to-earnings (P/E) ratio of 2.48 in the trailing twelve months and -2.94 on a forward basis. The price-to-book ratio is 1.91, and the price-to-sales ratio is 0.63. The company does not pay dividends, with a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Coherus Oncology, Inc.
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Visit website →Key Statistics
- Market Cap
- $174.05M
- P/E Ratio
- 2.48
- 52-Week High
- $1.89
- 52-Week Low
- $0.71
- Avg Volume
- 1.09M
- Beta
- 0.96
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 158